Orphan Drug Market to Reach $400 Billion by 2032 Despite Policy Shifts
Orphan drug sales are projected to reach $400 billion by 2032, accounting for over 21% of prescription drug sales. Recent policy changes expanded IRA exemptions for multi-indication orphan drugs and reauthorized pediatric review vouchers. Johnson & Johnson's Darzalex leads orphan drug sales with $31 billion projected revenue.
The orphan drug market continues to demonstrate remarkable resilience, with sales projected to reach over $400 billion by 2032 despite ongoing policy changes and pricing pressures. According to a new industry report, drugs for rare diseases will account for over 21% of all prescription pharmaceutical sales within the next seven years, up from 15% in 2022, as part of a nearly $1.9 trillion total prescription drug market.
The 2026 Orphan Drug Report highlights that the top eight orphan drugs will each sell over $6 billion in 2032, with today's orphan drug pipeline candidates collectively forecasted to top $100 billion in sales. The top selling orphan drug by 2032 is projected to be Johnson & Johnson's Darzalex for multiple myeloma, partially due to its subcutaneous formulation which doubles the franchise's effective lifespan. This positions Johnson & Johnson as the leading company in orphan drug sales with almost $31 billion in projected revenue.
Recent policy changes are positively influencing the market. Until 2025, only single-indication orphan drugs were exempt from Inflation Reduction Act price negotiations, but tweaks through the current administration's One Big Beautiful Bill Act expanded orphan exemptions to include multi-indication drugs. Additionally, the Rare Pediatric Disease Priority Review Voucher program was re-authorized in early 2026, promising faster FDA review times for products addressing rare childhood conditions.
Despite these supportive measures, orphan drugs' share of overall prescription drug sales is expected to fall over the next seven years, likely due to increased focus on blockbuster drugs for common conditions like obesity treatments. This trend relates to pharmaceutical companies' need to address a $300 billion loss-of-exclusivity gap.
At the state level, prescription drug affordability boards are clarifying their approach to orphan drugs. Oregon's board recently discussed how orphan drug exemptions are not drug-wide but depend on the specific indication for use. The board identified Cosentyx, Trulicity, and Vraylar as drugs that may create affordability challenges for healthcare systems or high out-of-pocket costs for patients, while also selecting Lantus Solostar insulin to fulfill statutory requirements.
The industry continues to navigate a changing regulatory landscape while maintaining momentum in rare disease drug development, with orphan drugs cementing their place as major players in the overall pharmaceutical market.